ProCE Banner Activity

Why I Have Renewed Hope for Better Treatment of Platinum-Resistant Ovarian Cancer

Clinical Thought
In this commentary, Kathleen Moore, MD, discusses new approaches and new agents that may meaningfully improve outcomes for women with platinum-resistant ovarian cancer.

Released: August 11, 2022

Expiration: August 10, 2023

No longer available for credit.

Share

Faculty

Kathleen Moore

Kathleen Moore, MD, MS

Associate Director, Clinical Research
Department of Gynecologic Oncology
Stephenson Cancer Center, University of Oklahoma
Oklahoma City, Oklahoma

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Faculty Disclosure

Primary Author

Kathleen Moore, MD, MS

Associate Director, Clinical Research
Department of Gynecologic Oncology
Stephenson Cancer Center, University of Oklahoma
Oklahoma City, Oklahoma

Kathleen Moore, MD: consultant/advisor/speaker: AstraZeneca, Aravive, Alkermes, BluePrint Pharma, Eisai, EMD Serono, Elevar, Genentech/Roche, Jiangsu Hengrui, Immunogen, INXmed, I-Mab, Mereo, Mersana, Myriad, Novartis, Onconova, Oncxerna, Tarveda, Verastem, VBL Therapeutics; researcher: PTC Therapeutics, Lilly, Merck, GlaxoSmithKline/Tesaro.